サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1540877

出血性疾患治療市場レポート：タイプ別、薬剤クラス別、流通チャネル別、エンドユーザー別、地域別 2024-2032

Bleeding Disorders Treatment Market Report by Type, Drug Class, Distribution Channel, End User, and Region 2024-2032

出版日
発行
IMARC
ページ情報
英文 141 Pages
納期
2～3営業日
カスタマイズ可能
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=146.82円
出血性疾患治療市場レポート：タイプ別、薬剤クラス別、流通チャネル別、エンドユーザー別、地域別 2024-2032
出版日: 2024年08月10日
発行: IMARC
ページ情報: 英文 141 Pages
納期: 2～3営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 図表
  • 目次
概要

出血性疾患治療市場の世界市場規模は2023年に150億米ドルに達しました。今後、IMARC Groupは、市場は2032年までに239億米ドルに達し、2024年から2032年の間に5.12%の成長率（CAGR）を示すと予測しています。

出血性疾患には、血友病AおよびB、フォンウィルブランド病、特発性血小板減少性紫斑病（ITP）、ビタミンKおよび第II、V、VII、X、XII因子の欠乏症が含まれます。これらの疾患は、血液凝固プロセスを阻害する疾患群です。これらの疾患はまた、傷害の後に大量かつ長引く出血を引き起こすこともあります。月経時の出血量が多い、あざができやすい、鼻血がよく出る、軽い切り傷からの出血が多い、関節からの出血が多いなどの症状があります。全血球算定（CBC）、血小板凝集能、出血時間などの血液検査によって診断されます。治療には、アドレノクロムモノセミカルバゾン、網膜出血、鼻出血、アミノカプロン酸、アプロチニン、鉄剤などの薬剤が用いられます。これらの薬剤は、特定の症状を最小限に抑え、患者の延命を助けることができます。出血性疾患の治療には、輸血、補充療法、凝固因子や血漿の注射も含まれます。

出血性疾患治療市場傾向：

大衆における出血性疾患の有病率の増加と、これらの病状に罹患しやすい老年人口の増加が、世界中の市場を牽引する主な要因の1つです。さらに、出血性疾患の治療に経済的支援を提供し、ヘルスケア費用を削減する健康保険政策の採用が増加していることも、市場にプラスの影響を与えています。さらに、多くの国の行政機関が献血や血漿提供に関する認識を高めています。また、献血キャンプを推進する取り組みも行っています。これとは別に、効果的な代替治療法が利用可能であるという認識が高まっていることも、市場に明るい展望をもたらしています。さらに、研究開発（R&D）活動やヘルスケア・インフラストラクチャーおよび診断技術の大幅な改善も、市場に良好な見通しをもたらすと予想されます。

本レポートで扱う主な質問

  • 世界の出血性疾患治療市場はこれまでどのように推移し、今後どのように推移していくのか？
  • COVID-19は世界の出血性疾患治療市場にどのような影響を与えたか？
  • 主要地域市場とは？
  • タイプ別の市場内訳は？
  • 薬剤クラス別の市場内訳は？
  • 販売チャネル別の市場内訳は？
  • エンドユーザー別の市場内訳は？
  • 業界のバリューチェーンにおける様々な段階とは？
  • 業界の主要な促進要因と課題は何か？
  • 世界の出血性疾患治療市場の構造と主要企業は？
  • 業界の競合の程度は？

目次

第1章 序文

第2章 調査範囲と調査手法

  • 調査の目的
  • ステークホルダー
  • データソース
    • 一次情報
    • 二次情報
  • 市場推定
    • ボトムアップアプローチ
    • トップダウンアプローチ
  • 調査手法

第3章 エグゼクティブサマリー

第4章 イントロダクション

  • 概要
  • 主要業界動向

第5章 世界の出血性疾患治療市場

  • 市場概要
  • 市場実績
  • COVID-19の影響
  • 市場予測

第6章 市場内訳：タイプ別

  • 血友病A
    • 市場動向
    • 市場予測
  • 血友病B
    • 市場動向
    • 市場予測
  • フォンウィルブランド病
    • 市場動向
    • 市場予測
  • その他
    • 市場動向
    • 市場予測

第7章 市場内訳：薬剤クラス別

  • 血漿由来凝固因子濃縮物
    • 市場動向
    • 主要セグメント
      • 第VIII因子
      • 第IX因子
      • フォンウィルブランド病の要因
      • 活性化プロトロンビン複合体濃縮物
    • 市場予測
  • 組換え凝固因子濃縮物
    • 市場動向
    • 主要セグメント
      • 第VIII因子
      • フォンウィルブランド病の要因
      • 第IX因子
    • 市場予測
  • デスモプレシン
    • 市場動向
    • 市場予測
  • 抗線維素溶解薬
    • 市場動向
    • 市場予測
  • フィブリンシーラント
    • 市場動向
    • 市場予測
  • その他
    • 市場動向
    • 市場予測

第8章 市場内訳：流通チャネル別

  • 病院薬局
    • 市場動向
    • 市場予測
  • 小売薬局
    • 市場動向
    • 市場予測
  • オンラインストア
    • 市場動向
    • 市場予測

第9章 市場内訳：エンドユーザー別

  • 病院
    • 市場動向
    • 市場予測
  • クリニック
    • 市場動向
    • 市場予測
  • 学術研究機関
    • 市場動向
    • 市場予測

第10章 市場内訳：地域別

  • 北米
    • 米国
    • カナダ
  • アジア太平洋地域
    • 中国
    • 日本
    • インド
    • 韓国
    • オーストラリア
    • インドネシア
    • その他
  • 欧州
    • ドイツ
    • フランス
    • 英国
    • イタリア
    • スペイン
    • ロシア
    • その他
  • ラテンアメリカ
    • ブラジル
    • メキシコ
    • その他
  • 中東・アフリカ
    • 市場動向
    • 市場内訳：国別
    • 市場予測

第11章 SWOT分析

  • 概要
  • 強み
  • 弱み
  • 機会
  • 脅威

第12章 バリューチェーン分析

第13章 ポーターのファイブフォース分析

  • 概要
  • 買い手の交渉力
  • 供給企業の交渉力
  • 競合の程度
  • 新規参入業者の脅威
  • 代替品の脅威

第14章 価格分析

第15章 競合情勢

  • 市場構造
  • 主要企業
  • 主要企業のプロファイル
    • AbbVie Inc
    • Alnylam Pharmaceuticals Inc.
    • Bayer AG
    • CSL Behring（CSL Limited）
    • Grifols S.A.
    • Johnson & Johnson
    • Novo Nordisk A/S
    • Octapharma AG
    • Pfizer Inc.
    • Sanofi S.A.
    • Takeda Pharmaceutical Company Limited
    • Wellona Pharma
図表

List of Figures

  • Figure 1: Global: Bleeding Disorders Treatment Market: Major Drivers and Challenges
  • Figure 2: Global: Bleeding Disorders Treatment Market: Sales Value (in Billion US$), 2018-2023
  • Figure 3: Global: Bleeding Disorders Treatment Market Forecast: Sales Value (in Billion US$), 2024-2032
  • Figure 4: Global: Bleeding Disorders Treatment Market: Breakup by Type (in %), 2023
  • Figure 5: Global: Bleeding Disorders Treatment Market: Breakup by Drug Class (in %), 2023
  • Figure 6: Global: Bleeding Disorders Treatment Market: Breakup by Distribution Channel (in %), 2023
  • Figure 7: Global: Bleeding Disorders Treatment Market: Breakup by End User (in %), 2023
  • Figure 8: Global: Bleeding Disorders Treatment Market: Breakup by Region (in %), 2023
  • Figure 9: Global: Bleeding Disorders Treatment (Hemophilia A) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 10: Global: Bleeding Disorders Treatment (Hemophilia A) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 11: Global: Bleeding Disorders Treatment (Hemophilia B) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 12: Global: Bleeding Disorders Treatment (Hemophilia B) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 13: Global: Bleeding Disorders Treatment (Von Willebrand Disease) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 14: Global: Bleeding Disorders Treatment (Von Willebrand Disease) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 15: Global: Bleeding Disorders Treatment (Other Types) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 16: Global: Bleeding Disorders Treatment (Other Types) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 17: Global: Bleeding Disorders Treatment (Plasma-derived Coagulation Factor Concentrates) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 18: Global: Bleeding Disorders Treatment (Plasma-derived Coagulation Factor Concentrates) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 19: Global: Bleeding Disorders Treatment (Recombinant Coagulation Factor Concentrates) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 20: Global: Bleeding Disorders Treatment (Recombinant Coagulation Factor Concentrates) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 21: Global: Bleeding Disorders Treatment (Desmopressin) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 22: Global: Bleeding Disorders Treatment (Desmopressin) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 23: Global: Bleeding Disorders Treatment (Antifibrinolytics) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 24: Global: Bleeding Disorders Treatment (Antifibrinolytics) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 25: Global: Bleeding Disorders Treatment (Fibrin Sealants) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 26: Global: Bleeding Disorders Treatment (Fibrin Sealants) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 27: Global: Bleeding Disorders Treatment (Other Drug Classes) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 28: Global: Bleeding Disorders Treatment (Other Drug Classes) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 29: Global: Bleeding Disorders Treatment (Hospital Pharmacies) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 30: Global: Bleeding Disorders Treatment (Hospital Pharmacies) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 31: Global: Bleeding Disorders Treatment (Retail Pharmacies) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 32: Global: Bleeding Disorders Treatment (Retail Pharmacies) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 33: Global: Bleeding Disorders Treatment (Online Stores) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 34: Global: Bleeding Disorders Treatment (Online Stores) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 35: Global: Bleeding Disorders Treatment (Hospitals) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 36: Global: Bleeding Disorders Treatment (Hospitals) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 37: Global: Bleeding Disorders Treatment (Clinics) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 38: Global: Bleeding Disorders Treatment (Clinics) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 39: Global: Bleeding Disorders Treatment (Academic and Research Institutes) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 40: Global: Bleeding Disorders Treatment (Academic and Research Institutes) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 41: North America: Bleeding Disorders Treatment Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 42: North America: Bleeding Disorders Treatment Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 43: United States: Bleeding Disorders Treatment Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 44: United States: Bleeding Disorders Treatment Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 45: Canada: Bleeding Disorders Treatment Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 46: Canada: Bleeding Disorders Treatment Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 47: Asia-Pacific: Bleeding Disorders Treatment Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 48: Asia-Pacific: Bleeding Disorders Treatment Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 49: China: Bleeding Disorders Treatment Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 50: China: Bleeding Disorders Treatment Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 51: Japan: Bleeding Disorders Treatment Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 52: Japan: Bleeding Disorders Treatment Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 53: India: Bleeding Disorders Treatment Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 54: India: Bleeding Disorders Treatment Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 55: South Korea: Bleeding Disorders Treatment Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 56: South Korea: Bleeding Disorders Treatment Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 57: Australia: Bleeding Disorders Treatment Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 58: Australia: Bleeding Disorders Treatment Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 59: Indonesia: Bleeding Disorders Treatment Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 60: Indonesia: Bleeding Disorders Treatment Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 61: Others: Bleeding Disorders Treatment Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 62: Others: Bleeding Disorders Treatment Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 63: Europe: Bleeding Disorders Treatment Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 64: Europe: Bleeding Disorders Treatment Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 65: Germany: Bleeding Disorders Treatment Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 66: Germany: Bleeding Disorders Treatment Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 67: France: Bleeding Disorders Treatment Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 68: France: Bleeding Disorders Treatment Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 69: United Kingdom: Bleeding Disorders Treatment Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 70: United Kingdom: Bleeding Disorders Treatment Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 71: Italy: Bleeding Disorders Treatment Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 72: Italy: Bleeding Disorders Treatment Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 73: Spain: Bleeding Disorders Treatment Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 74: Spain: Bleeding Disorders Treatment Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 75: Russia: Bleeding Disorders Treatment Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 76: Russia: Bleeding Disorders Treatment Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 77: Others: Bleeding Disorders Treatment Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 78: Others: Bleeding Disorders Treatment Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 79: Latin America: Bleeding Disorders Treatment Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 80: Latin America: Bleeding Disorders Treatment Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 81: Brazil: Bleeding Disorders Treatment Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 82: Brazil: Bleeding Disorders Treatment Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 83: Mexico: Bleeding Disorders Treatment Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 84: Mexico: Bleeding Disorders Treatment Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 85: Others: Bleeding Disorders Treatment Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 86: Others: Bleeding Disorders Treatment Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 87: Middle East and Africa: Bleeding Disorders Treatment Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 88: Middle East and Africa: Bleeding Disorders Treatment Market: Breakup by Country (in %), 2023
  • Figure 89: Middle East and Africa: Bleeding Disorders Treatment Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 90: Global: Bleeding Disorders Treatment Industry: SWOT Analysis
  • Figure 91: Global: Bleeding Disorders Treatment Industry: Value Chain Analysis
  • Figure 92: Global: Bleeding Disorders Treatment Industry: Porter's Five Forces Analysis

List of Tables

  • Table 1: Global: Bleeding Disorders Treatment Market: Key Industry Highlights, 2023 and 2032
  • Table 2: Global: Bleeding Disorders Treatment Market Forecast: Breakup by Type (in Million US$), 2024-2032
  • Table 3: Global: Bleeding Disorders Treatment Market Forecast: Breakup by Drug Class (in Million US$), 2024-2032
  • Table 4: Global: Bleeding Disorders Treatment Market Forecast: Breakup by Distribution Channel (in Million US$), 2024-2032
  • Table 5: Global: Bleeding Disorders Treatment Market Forecast: Breakup by End User (in Million US$), 2024-2032
  • Table 6: Global: Bleeding Disorders Treatment Market Forecast: Breakup by Region (in Million US$), 2024-2032
  • Table 7: Global: Bleeding Disorders Treatment Market: Competitive Structure
  • Table 8: Global: Bleeding Disorders Treatment Market: Key Players
目次
Product Code: SR112024A6567

The global bleeding disorders treatment market size reached US$ 15.0 Billion in 2023. Looking forward, IMARC Group expects the market to reach US$ 23.9 Billion by 2032, exhibiting a growth rate (CAGR) of 5.12% during 2024-2032.

Bleeding disorders involve hemophilia A and B, Von Willebrand disease, idiopathic thrombocytopenic purpura (ITP), and deficiencies of vitamin K and factors II, V, VII, X, and XII. They are a class of conditions that disrupt the blood clotting process in an individual. They can also lead to heavy and prolonged bleeding after an injury. They have symptoms, including heavy menstrual bleeding, easy bruising, frequent nosebleeds, excessive bleeding from minor cuts, and joint bleeding. They are diagnosed through blood tests of complete blood count (CBC), platelet aggregation, and bleeding time. Their treatment comprises medications, including adrenochrome monosemicarbazone, retinal hemorrhage, epistaxis, aminocaproic acid, aprotinin, and iron supplements. These medications can aid in minimizing specific symptoms and prolonging the life of patients. Bleeding disorders treatment also includes blood transfusion, replacement therapy, and injections of a clotting factor and plasma.

Bleeding Disorders Treatment Market Trends:

The increasing prevalence of bleeding disorders among the masses and the rising geriatric population, which is more susceptible to these medical conditions, are among the key factors driving the market around the world. Moreover, the growing adoption of health insurance policies that provide financial assistance for bleeding disorders treatment and reduce healthcare expenses is influencing the market positively. In addition, governing agencies of numerous countries are generating awareness about blood and plasma donation. They are also undertaking initiatives to promote blood donation camps. Apart from this, the increasing awareness about the availability of effective treatment alternatives is creating a positive outlook for the market. Furthermore, research and development (R&D) activities and considerable improvements in the healthcare infrastructure and diagnostic technologies are expected to provide a favorable outlook to the market.

Key Market Segmentation:

IMARC Group provides an analysis of the key trends in each sub-segment of the global bleeding disorders treatment market report, along with forecasts at the global, regional and country level from 2024-2032. Our report has categorized the market based on type, drug class, distribution channel and end user.

Breakup by Type:

Hemophilia A

Hemophilia B

Von Willebrand Disease

Others

Breakup by Drug Class:

Plasma-derived Coagulation Factor Concentrates

Factor VIII

Factor IX

Factor for Von Willebrand Disease

Activated Prothrombin Complex Concentrate

Recombinant Coagulation Factor Concentrates

Factor VIII

Factor for Von Willebrand Disease

Factor IX

Desmopressin

Antifibrinolytics

Fibrin Sealants

Others

Breakup by Distribution Channel:

Hospital Pharmacies

Retail Pharmacies

Online Stores

Breakup by End User:

Hospitals

Clinics

Academic and Research Institutes

Breakup by Region:

North America

United States

Canada

Asia-Pacific

China

Japan

India

South Korea

Australia

Indonesia

Others

Europe

Germany

France

United Kingdom

Italy

Spain

Russia

Others

Latin America

Brazil

Mexico

Others

Middle East and Africa

Competitive Landscape:

The competitive landscape of the industry has also been examined along with the profiles of the key players being AbbVie Inc, Alnylam Pharmaceuticals Inc., Bayer AG, CSL Behring (CSL Limited), Grifols S.A., Johnson & Johnson, Novo Nordisk A/S, Octapharma AG, Pfizer Inc., Sanofi S.A., Takeda Pharmaceutical Company Limited and Wellona Pharma.

Key Questions Answered in This Report:

  • How has the global bleeding disorders treatment market performed so far and how will it perform in the coming years?
  • What has been the impact of COVID-19 on the global bleeding disorders treatment market?
  • What are the key regional markets?
  • What is the breakup of the market based on the type?
  • What is the breakup of the market based on the drug class?
  • What is the breakup of the market based on the distribution channel?
  • What is the breakup of the market based on the end user?
  • What are the various stages in the value chain of the industry?
  • What are the key driving factors and challenges in the industry?
  • What is the structure of the global bleeding disorders treatment market and who are the key players?
  • What is the degree of competition in the industry?

Table of Contents

1 Preface

2 Scope and Methodology

  • 2.1 Objectives of the Study
  • 2.2 Stakeholders
  • 2.3 Data Sources
    • 2.3.1 Primary Sources
    • 2.3.2 Secondary Sources
  • 2.4 Market Estimation
    • 2.4.1 Bottom-Up Approach
    • 2.4.2 Top-Down Approach
  • 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

  • 4.1 Overview
  • 4.2 Key Industry Trends

5 Global Bleeding Disorders Treatment Market

  • 5.1 Market Overview
  • 5.2 Market Performance
  • 5.3 Impact of COVID-19
  • 5.4 Market Forecast

6 Market Breakup by Type

  • 6.1 Hemophilia A
    • 6.1.1 Market Trends
    • 6.1.2 Market Forecast
  • 6.2 Hemophilia B
    • 6.2.1 Market Trends
    • 6.2.2 Market Forecast
  • 6.3 Von Willebrand Disease
    • 6.3.1 Market Trends
    • 6.3.2 Market Forecast
  • 6.4 Others
    • 6.4.1 Market Trends
    • 6.4.2 Market Forecast

7 Market Breakup by Drug Class

  • 7.1 Plasma-derived Coagulation Factor Concentrates
    • 7.1.1 Market Trends
    • 7.1.2 Key Segments
      • 7.1.2.1 Factor VIII
      • 7.1.2.2 Factor IX
      • 7.1.2.3 Factor for Von Willebrand Disease
      • 7.1.2.4 Activated Prothrombin Complex Concentrate
    • 7.1.3 Market Forecast
  • 7.2 Recombinant Coagulation Factor Concentrates
    • 7.2.1 Market Trends
    • 7.2.2 Key Segments
      • 7.2.2.1 Factor VIII
      • 7.2.2.2 Factor for Von Willebrand Disease
      • 7.2.2.3 Factor IX
    • 7.2.3 Market Forecast
  • 7.3 Desmopressin
    • 7.3.1 Market Trends
    • 7.3.2 Market Forecast
  • 7.4 Antifibrinolytics
    • 7.4.1 Market Trends
    • 7.4.2 Market Forecast
  • 7.5 Fibrin Sealants
    • 7.5.1 Market Trends
    • 7.5.2 Market Forecast
  • 7.6 Others
    • 7.6.1 Market Trends
    • 7.6.2 Market Forecast

8 Market Breakup by Distribution Channel

  • 8.1 Hospital Pharmacies
    • 8.1.1 Market Trends
    • 8.1.2 Market Forecast
  • 8.2 Retail Pharmacies
    • 8.2.1 Market Trends
    • 8.2.2 Market Forecast
  • 8.3 Online Stores
    • 8.3.1 Market Trends
    • 8.3.2 Market Forecast

9 Market Breakup by End User

  • 9.1 Hospitals
    • 9.1.1 Market Trends
    • 9.1.2 Market Forecast
  • 9.2 Clinics
    • 9.2.1 Market Trends
    • 9.2.2 Market Forecast
  • 9.3 Academic and Research Institutes
    • 9.3.1 Market Trends
    • 9.3.2 Market Forecast

10 Market Breakup by Region

  • 10.1 North America
    • 10.1.1 United States
      • 10.1.1.1 Market Trends
      • 10.1.1.2 Market Forecast
    • 10.1.2 Canada
      • 10.1.2.1 Market Trends
      • 10.1.2.2 Market Forecast
  • 10.2 Asia-Pacific
    • 10.2.1 China
      • 10.2.1.1 Market Trends
      • 10.2.1.2 Market Forecast
    • 10.2.2 Japan
      • 10.2.2.1 Market Trends
      • 10.2.2.2 Market Forecast
    • 10.2.3 India
      • 10.2.3.1 Market Trends
      • 10.2.3.2 Market Forecast
    • 10.2.4 South Korea
      • 10.2.4.1 Market Trends
      • 10.2.4.2 Market Forecast
    • 10.2.5 Australia
      • 10.2.5.1 Market Trends
      • 10.2.5.2 Market Forecast
    • 10.2.6 Indonesia
      • 10.2.6.1 Market Trends
      • 10.2.6.2 Market Forecast
    • 10.2.7 Others
      • 10.2.7.1 Market Trends
      • 10.2.7.2 Market Forecast
  • 10.3 Europe
    • 10.3.1 Germany
      • 10.3.1.1 Market Trends
      • 10.3.1.2 Market Forecast
    • 10.3.2 France
      • 10.3.2.1 Market Trends
      • 10.3.2.2 Market Forecast
    • 10.3.3 United Kingdom
      • 10.3.3.1 Market Trends
      • 10.3.3.2 Market Forecast
    • 10.3.4 Italy
      • 10.3.4.1 Market Trends
      • 10.3.4.2 Market Forecast
    • 10.3.5 Spain
      • 10.3.5.1 Market Trends
      • 10.3.5.2 Market Forecast
    • 10.3.6 Russia
      • 10.3.6.1 Market Trends
      • 10.3.6.2 Market Forecast
    • 10.3.7 Others
      • 10.3.7.1 Market Trends
      • 10.3.7.2 Market Forecast
  • 10.4 Latin America
    • 10.4.1 Brazil
      • 10.4.1.1 Market Trends
      • 10.4.1.2 Market Forecast
    • 10.4.2 Mexico
      • 10.4.2.1 Market Trends
      • 10.4.2.2 Market Forecast
    • 10.4.3 Others
      • 10.4.3.1 Market Trends
      • 10.4.3.2 Market Forecast
  • 10.5 Middle East and Africa
    • 10.5.1 Market Trends
    • 10.5.2 Market Breakup by Country
    • 10.5.3 Market Forecast

11 SWOT Analysis

  • 11.1 Overview
  • 11.2 Strengths
  • 11.3 Weaknesses
  • 11.4 Opportunities
  • 11.5 Threats

12 Value Chain Analysis

13 Porters Five Forces Analysis

  • 13.1 Overview
  • 13.2 Bargaining Power of Buyers
  • 13.3 Bargaining Power of Suppliers
  • 13.4 Degree of Competition
  • 13.5 Threat of New Entrants
  • 13.6 Threat of Substitutes

14 Price Analysis

15 Competitive Landscape

  • 15.1 Market Structure
  • 15.2 Key Players
  • 15.3 Profiles of Key Players
    • 15.3.1 AbbVie Inc
      • 15.3.1.1 Company Overview
      • 15.3.1.2 Product Portfolio
      • 15.3.1.3 Financials
      • 15.3.1.4 SWOT Analysis
    • 15.3.2 Alnylam Pharmaceuticals Inc.
      • 15.3.2.1 Company Overview
      • 15.3.2.2 Product Portfolio
      • 15.3.2.3 Financials
      • 15.3.2.4 SWOT Analysis
    • 15.3.3 Bayer AG
      • 15.3.3.1 Company Overview
      • 15.3.3.2 Product Portfolio
      • 15.3.3.3 Financials
      • 15.3.3.4 SWOT Analysis
    • 15.3.4 CSL Behring (CSL Limited)
      • 15.3.4.1 Company Overview
      • 15.3.4.2 Product Portfolio
    • 15.3.5 Grifols S.A.
      • 15.3.5.1 Company Overview
      • 15.3.5.2 Product Portfolio
      • 15.3.5.3 Financials
      • 15.3.5.4 SWOT Analysis
    • 15.3.6 Johnson & Johnson
      • 15.3.6.1 Company Overview
      • 15.3.6.2 Product Portfolio
      • 15.3.6.3 Financials
      • 15.3.6.4 SWOT Analysis
    • 15.3.7 Novo Nordisk A/S
      • 15.3.7.1 Company Overview
      • 15.3.7.2 Product Portfolio
      • 15.3.7.3 Financials
      • 15.3.7.4 SWOT Analysis
    • 15.3.8 Octapharma AG
      • 15.3.8.1 Company Overview
      • 15.3.8.2 Product Portfolio
      • 15.3.8.3 SWOT Analysis
    • 15.3.9 Pfizer Inc.
      • 15.3.9.1 Company Overview
      • 15.3.9.2 Product Portfolio
      • 15.3.9.3 Financials
      • 15.3.9.4 SWOT Analysis
    • 15.3.10 Sanofi S.A.
      • 15.3.10.1 Company Overview
      • 15.3.10.2 Product Portfolio
      • 15.3.10.3 Financials
      • 15.3.10.4 SWOT Analysis
    • 15.3.11 Takeda Pharmaceutical Company Limited
      • 15.3.11.1 Company Overview
      • 15.3.11.2 Product Portfolio
      • 15.3.11.3 Financials
      • 15.3.11.4 SWOT Analysis
    • 15.3.12 Wellona Pharma
      • 15.3.12.1 Company Overview
      • 15.3.12.2 Product Portfolio